Literature DB >> 10942164

Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium.

C Strohm1, T Barancik, M L Brühl, S A Kilian, W Schaper.   

Abstract

Our previous studies suggested a protective role of the extracellular signal-regulated kinases (ERKs) cascade in ischemic preconditioning (IP) in the porcine heart. To test this hypothesis further, we studied the influence of the novel specific inhibitors of mitogen-activated protein kinase kinases (MEK 1/2) PD98059 (PD) and UO126 (UO) in IP. The substances were infused intramyocardially and UO also systemically in anesthetized, ventilated, open-chested, male pigs. The local intramyocardial PD and UO infusions occurred before IP and during both reperfusion (RP) phases of IP via four pairs of needles (three pairs verum, one solvent) into the risk area (RA). The IP design included two cycles of 10-min left anterior descending artery (LAD) occlusion and 10 min RP, followed by 40 min of occlusion (index ischemia) and of 60 min of RP. Biopsies of the areas of drug infusion were taken after the second RP cycle of IP. By Western blot analysis, the phosphorylation of ERK 1/2 and of the downstream transcription factor Elk-1 were measured, and the activities of the ERKs were tested by in gel phosphorylation. Only small infarcts were detected in the control group animals with the IP period [infarct size (IS), infarct area/risk area; IS, 2.5+/-0.1%]. Significant wedge-shaped infarcts were seen around the area of the PD and UO infusions. The effects of PD and UO were concentration dependent. The maximal dose of UO126 (7.5 mg systemically) was associated with an IS of 68.7+/-2.0%. At the end of IP, we observed a significant increase in phosphorylation and activities of ERKs. PD (50 microM) induced a 50% inhibition of ERK-1 and 56% of ERK-2 activities. Phosphorylated ERK-1 and ERK-2 were decreased after microinfusion of both PD and UO (50 microM). Microinfusion of 50 microM PD also significantly decreased the phosphorylation of Elk-1 (to 59.2+/-8.3% of control conditions). We demonstrate for the first time in vivo that the inhibition of ERKs by PD and UO results in a complete cancellation of IP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942164     DOI: 10.1097/00005344-200008000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  23 in total

1.  Cardiomyocyte overexpression of the α1A-adrenergic receptor in the rat phenocopies second but not first window preconditioning.

Authors:  Xin Zhao; Jiyeon Park; David Ho; Shumin Gao; Lin Yan; Hui Ge; Siiri Iismaa; Lin Lin; Bin Tian; Dorothy E Vatner; Robert M Graham; Stephen F Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels.

Authors:  Janet R Manning; Gregory Carpenter; Darius R Porter; Stacey L House; Daniel A Pietras; Thomas Doetschman; Jo el J Schultz
Journal:  Growth Factors       Date:  2012-02-06       Impact factor: 2.511

3.  Inositol 1,4,5-triphosphate receptors and NAD(P)H mediate Ca2+ signaling required for hypoxic preconditioning of hippocampal neurons.

Authors:  P E Bickler; C S Fahlman; J Gray; W McKleroy
Journal:  Neuroscience       Date:  2009-02-13       Impact factor: 3.590

4.  Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency.

Authors:  Zheqing P Cai; Zhenyun Shen; Luc Van Kaer; Lewis C Becker
Journal:  FASEB J       Date:  2008-08-26       Impact factor: 5.191

5.  Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart.

Authors:  Tána Ravingerová; Jana Matejíková; Jan Neckár; Eva Andelová; Frantisek Kolár
Journal:  Mol Cell Biochem       Date:  2006-10-03       Impact factor: 3.396

6.  Inhibition of ROS-activated ERK1/2 pathway contributes to the protection of H2S against chemical hypoxia-induced injury in H9c2 cells.

Authors:  Xiao-Bian Dong; Chun-Tao Yang; Dong-Dan Zheng; Li-Qiu Mo; Xiu-Yu Wang; Ai-Ping Lan; Fen Hu; Pei-Xi Chen; Jian-Qiang Feng; Mei-Fen Zhang; Xin-Xue Liao
Journal:  Mol Cell Biochem       Date:  2011-12-02       Impact factor: 3.396

7.  Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways.

Authors:  Bo Yin; Xu-Wei Hou; Mei-Li Lu
Journal:  Acta Pharmacol Sin       Date:  2018-07-20       Impact factor: 6.150

Review 8.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

9.  Akt and Erk1/2 activate the ornithine decarboxylase/polyamine system in cardioprotective ischemic preconditioning in rats: the role of mitochondrial permeability transition pores.

Authors:  Hao Zhang; Guo Xue; Weihua Zhang; Lina Wang; Hong Li; Li Zhang; Fanghao Lu; Shuzhi Bai; Yan Lin; Yu Lou; Changqing Xu; Yajun Zhao
Journal:  Mol Cell Biochem       Date:  2014-01-24       Impact factor: 3.396

10.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.

Authors:  Anindita Das; Fadi N Salloum; Lei Xi; Yuan J Rao; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.